Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model

X Yao1, DL Anderson1, SA Ross1, DG Lang1, BZ Desai1, DC Cooper2, P Wheelan3, MS McIntyre1, ML Bergquist2, KI MacKenzie1,4, JD Becherer1 and MA Hashim1

1Department of Biochemical & Analytical Pharmacology, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Discovery Statistics, GlaxoSmithKline, Research Triangle Park, NC, USA and 3Drug Metabolism & Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, NC, USA

Background and purpose: Drug-induced prolongation of the QT interval can lead to torsade de pointes, a life-threatening ventricular arrhythmia. Finding appropriate assays from among the plethora of options available to predict reliably this serious adverse effect in humans remains a challenging issue for the discovery and development of drugs. The purpose of the present study was to develop and verify a reliable and relatively simple approach for assessing, during preclinical development, the propensity of drugs to prolong the QT interval in humans.

Experimental approach: Sixteen marketed drugs from various pharmacological classes with a known incidence—or lack thereof—of QT prolongation in humans were examined in hERG (human ether-a-go-go-related gene) patch-clamp assay and an anaesthetized guinea-pig assay for QT prolongation using specific protocols. Drug concentrations in perfusates from hERG assays and plasma samples from guinea-pigs were determined using liquid chromatography-mass spectrometry.

Key results: Various pharmacological agents that inhibit hERG currents prolong the QT interval in anaesthetized guinea-pigs in a manner similar to that seen in humans and at comparable drug exposures. Several compounds not associated with QT prolongation in humans failed to prolong the QT interval in this model.

Conclusions and implications: Analysis of hERG inhibitory potency in conjunction with drug exposures and QT interval measurements in anaesthetized guinea-pigs can reliably predict, during preclinical drug development, the risk of human QT prolongation. A strategy is proposed for mitigating the risk of QT prolongation of new chemical entities during early lead optimization.

British Journal of Pharmacology (2008) 154, 1446–1456; doi:10.1038/bjp.2008.267; published online 30 June 2008

Keywords: drug development; drug-induced QT prolongation; patch clamping; surface ECG (electrocardiogram); TdP (torsade de pointes); hERG potassium channel

Abbreviations: hERG, human ether-a-go-go-related gene; QTc, the heart rate corrected QT interval of the ECG; TdP, torsade de pointes

Introduction

Drug-induced QT prolongation leading to serious ventricular arrhythmias, such as torsade de pointes (TdP), poses a major safety consideration for the development and use of new drug candidates (Crumb and Cavero, 1999). TdP is a unique form of polymorphic ventricular tachycardia that may result in a worsening of the patient’s cardiac condition and/or sudden death. The incidence of TdP with cardiac pro-arrhythmic drugs is 1–8%, but the incidence with non-cardiac drugs is considerably lower, approximately 1:10 000–1:100 000 (Darpo, 2001). TdP is typically not seen in clinical trials because of its infrequent occurrence. The mechanism of TdP remains unclear and this uncertainty makes it difficult to predict it in the early stages of drug development. However, TdP is always associated with prolongation of the QT interval of the surface ECG. Consequently, the presence of a prolonged QT interval has become a surrogate marker for the possible development of TdP. Thus, any evidence indicating a QT prolongation by a new drug is a significant concern in drug development, as it raises the risk of TdP. QT prolongation issues have
significantly affected the pharmaceutical industry. The clinical development of candidate compounds has been halted as a result of QT prolongation and marketed drugs have been withdrawn due to a small number of TdP incidents in humans. Some notable examples include cisapride, grepafloxacin and terfenadine. Because of this significant safety issue, regulatory agencies including the Food and Drug Administration (FDA), the Committee for Proprietary Medicinal Products (CPMP) and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) have increasingly required pharmaceutical companies to take serious measures to minimize the risk of drug-induced TdP (Committee for Proprietary Medicinal Products, 1997; ICH S7A, B; ICH E14).

To protect patients and address the concerns of regulatory agencies, pharmaceutical companies have employed a number of preclinical models to evaluate the likelihood of a compound prolonging the QT interval. Clearly, no single assay is sufficient to predict the risk of TdP in humans. This concept is also reflected in the final preclinical guidelines (ICH S7A and S7B, http://www.ich.org), where both an in vitro \( I_{Kr} \) (rapidly activating delayed rectifier potassium current) (hERG (human ether a-go-go-related gene)) assay and an in vivo QT assay are recommended to assess a candidate’s QT prolongation risk. Among the in vitro hERG assays, functional hERG testing using conventional patch-clamp electrophysiology is still the most relevant methodology and remains the gold standard. The telemetered dog and monkey in vivo models are frequently used for ECG investigations (Hammond et al., 2001). However, these assays are often delayed until the late stage of preclinical development, due to cost and resource constraints. Ideally, potential QT prolongation issues need to be identified earlier in drug development to guide structure–activity relationship to minimize the risk of QT prolongation in new chemical entities. Thus, there is a critical need for a reliable approach for accurately and expeditiously predicting the QT prolongation liability of many compounds during the early stage of drug development using a less expensive, but predictive, alternative to the dog or monkey. Among small species, the guinea-pig, unlike rat and mouse, has a cardiac action potential and ECG that are similar to humans, and thus represents a practical, small animal model for assessing QT interval prolongation early in the drug development process. This species is also listed as a suitable model for QT assessment in the ICH S7B guidelines.

Thus, to predict potential QT issues preclinically, we set out to develop a strategy of using a guinea-pig QT model in combination with a hERG functional assay, which we describe herein. This strategy stems from a systematic examination of the relationships between the potency of hERG inhibition in conjunction with drug exposures, the change of QT interval in a guinea-pig model and QT prolongation/TdP in humans for a variety of therapeutic agents. Sixteen marketed drugs were examined in the hERG electrophysiology and anaesthetized guinea-pig QT measurement assays, protocols for which were optimized to yield consistent, robust data with ease of use. Eight drugs that have been associated with QT prolongation and TdP incidents in humans, three drugs that caused QT prolongation without TdP reported in humans and five drugs that had no association with QT prolongation and TdP in humans were included.

**Methods**

**Selection of drugs**
Sixteen marketed drugs were selected to cover a wide range of cardiovascular and non-cardiovascular therapeutic classes, including antiarrhythmics, a gastrointestinal prokinetic, anti-histamines, an anti-oestrogen, antibiotics, antipsychotics, antithrombotics and angiotensin-converting enzyme inhibitors. As shown in Table 1, these drugs were divided into three groups based on their QT prolongation effects and the numbers of TdP incidents in humans. Group A contained eight drugs that induce QT prolongation with TdP incidents reported. The three drugs in group B cause QT prolongation but have not been reported to cause TdP. Five group C drugs do not cause QT prolongation or TdP incidents. Commercial availability was also considered for the selection of drugs. The source of each drug is listed in Supplementary Table 1.

Medline searches were performed to identify the QT effects and TdP incidents for the drugs used in this study. The majority of \( C_{\text{max}} \) (maximum plasma concentration) values and ranges for protein binding were found in *Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition* (Hardman and Limbird, 2006a, b). Otherwise, they were found in individual publications indicated in Table 1. The highest \( C_{\text{max}} \) Values and the lowest values of protein binding were chosen when more than two values were available. Maximum free drug concentration (free \( C_{\text{max}} \)) was calculated using the following equation:

\[
\text{Free } C_{\text{max}} = \frac{\text{Total } C_{\text{max}} \times (1 - \text{protein bound fraction})}{100}
\]

where the total \( C_{\text{max}} \) was the peak total plasma concentration and the protein-bound fraction is the proportion of compound bound to plasma proteins. These plasma levels are summarized in Table 1.

**Cell preparation and voltage-clamp recordings of hERG currents**

The hERG potassium channels were stably expressed in the Chinese hamster ovary (CHO)-K1 cells. The CHO-K1 cells were maintained in cell media that contained 90% Iscove’s modified Dulbecco’s medium, 10% foetal bovine serum, 1% HT supplement, 1% non-essential amino acid (NEAA), penicillin G sodium 100 U mL\(^{-1}\), streptomycin sulphate 100 \(\mu\)g mL\(^{-1}\) and geneticin 500 \(\mu\)g mL\(^{-1}\). Confluent cells in flasks were rinsed once with PBS prior to passage. The flasks were incubated with Versene (EDTA) 1:5000 for 5 min at 37°C to detach the cells from the flasks. Cells used in electrophysiology experiments were plated on glass cover slips 24–48 h prior to use.

hERG current recordings were performed using the whole-cell patch clamp configuration with an AxonMultiClamp 700A amplifier (Axon Instruments, Union City, CA, USA). Voltage clamp protocols were controlled using pClamp9 (Axon Instruments) acquisition and analysis software as
The GlaxoSmithKline Institutional Animal Care and Use Committee according to IACUC protocol 593.03. The guinea-pigs (Charles River, Raleigh, NC, USA) arrived at the animal service department at least 1 week before the study. The guinea-pigs were housed in fibreglass cages with food and water available ad libitum. They were fasted overnight before the study procedure.

Experimental procedures and recordings of ECG, blood pressure and heart rate in guinea-pigs

Male Hartley guinea-pigs weighing 450–550 g were fasted 18 h prior to experimental procedures. The guinea-pigs were anaesthetized using an intraperitoneal injection of Inactin (thiobutabarbital sodium salt) 100–120 mg kg\(^{-1}\) and urethane 1.2 g kg\(^{-1}\). A tracheotomy was performed and the guinea-pigs were mechanically ventilated (Harvard Apparatus, Holliston, MA, USA). Tidal volumes were set at 3 mL with an initial ventilation rate of 40–42 strokes per minute and supplemental oxygen was added. Final ventilation settings were determined using expired CO\(_2\) measurements obtained from a micro-capnograph (Columbus Instruments, Columbus, OH, USA). Oxygen saturation values were monitored using a pulse oximeter (Surgivet, Waukesha, WI, USA). The animal was placed on a heat pad with circulating water at a temperature of 37–39 °C. The jugular vein and the carotid artery were cannulated for drug administration and blood pressure monitoring, respectively. ECG pin electrodes were positioned for the standard limb lead and chest lead configuration. ECG signals were measured from lead II or V4 lead depending on the integrity of the signal response. The carotid arterial catheter through a pressure transducer and ECG cable signals were relayed to a Gould Physiograph with outputs to a data acquisition system (Ponemah, St Paul, MN, USA). The blood pressure and ECG were sampled at

Table 1: Published data regarding QT prolongation (LQT) and TdP incidence, maximal plasma concentrations and protein binding in human clinical use

| Group | Drug | Incidence | Human total plasma C\(_{\text{max}}\) (\(\mu\)M) | Protein binding (%) | Reference |
|-------|------|-----------|---------------------------------|-------------------|-----------|
| A     | Amiodarone | LQT, TdP | 3.67 | 96 | Hardman and Limbird (2006a) |
|       | Cisapride    | LQT, TdP | 0.13 | 97.5 | Meuldermans et al. (1988); Hardman and Limbird (2006a) |
|       | Droperidol   | LQT, TdP | 4.098 | 90 | Fischler et al. (1986) |
|       | Haloperidol  | LQT, TdP | 0.106 | 90 | Hardman and Limbird (2006a) |
|       | Quinidine    | LQT, TdP | 12 | 84 | Hardman and Limbird (2006a) |
|       | D,L-Sotalol  | LQT, TdP | 18.4 | 0 | Hardman and Limbird (2006b) |
|       | Sparfloxacin | LQT, TdP | 9.68 | 37 | Shimada et al. (1993); Morganroth et al. (1999) |
|       | Terfenadine  | LQT, TdP | 0.12 | 97 | Monahan et al. (1990); González and Estes (1998) |
| B     | Sparfloxacin | LQT | 8.68 | 37 | Hardman and Limbird (2006a) |
|       | Tamoxifen    | LQT | 0.493 | >98 | Hardman and Limbird (2006a) |
|       | Ziprasidone  | LQT | 0.228 | >99.8 | Aweeka et al. (2000); Miceli et al. (2000) |
| C     | Amoxicillin  | None | 158.7 | 18 | Hardman and Limbird (2006a) |
|       | Aspirin      | None | 110.8 | 80 | Hardman and Limbird (2006c) |
|       | Captopril    | None | 3.61 | 25 | Song and White (2002) |
|       | Propranolol  | None | 0.22 | 85 | Hardman and Limbird (2006a) |
|       | Verapamil    | None | 0.55 | 88 | Hardman and Limbird (2006a) |

Abbreviation: TdP, torsade de pointes.

*Case report of LQT during overdose.
rates of 250 and 1000 Hz, respectively. The heart rate values were obtained from the ECG channel.

All animals were allowed to stabilize for a 40- to 50-min period after being instrumented prior to the start of data collection. Data were collected over a 5-min control period before drug administration. A vehicle was used to dissolve the compound initially. Normal physiological saline was then added to reach the desired concentration for the 1 mL infusion volume. Guinea-pigs received a single dose of compound or vehicle at a time. To minimize indirect haemodynamic effects, all animals within each dose group were given the same infusion volume. All compounds were infused in all animals at a rate of 1 mL over a 10-min period for each dose given. Data were recorded for 30 min post-infusion. Each drug (or an equal volume of vehicle) was administered intravenously at the doses shown in Supplementary Table 1 to five animals per dose, infused over 10 min. After infusion, the animals were monitored for 30 min to assess compound effects. Blood samples (0.4 mL) for determination of drug concentrations were collected 1 and 31 min post-infusion. For each vehicle type, five control animals were infused with equal volumes of vehicle following an identical protocol to the drug-treated groups.

The QT interval is corrected for heart rate changes (QTc) by using Bazett’s formula:

$$\text{QTc} = \left( \frac{\text{QT interval in milliseconds}}{\text{RR interval in seconds}} \right)^{1/2}$$

where QTc represents the QT interval corrected for heart rate, QT represents the interval from the beginning of the Q wave (onset of ventricular depolarization) through the end of the T wave (completion of ventricular repolarization) and the R–R interval is the time between two consecutive heart beats and is the inverse of the heart rate.

All parameters were averaged on a beat-to-beat basis every 10 s and reported out every 30 s to a data table. The baseline values of mean arterial blood pressure, heart rate or QTc interval consisted of a 5 min average of measurements before drug administration.

For each animal, the post-infusion QTc measurements (60 measurements recorded over 30 min) are summarized in the single number ‘baseline-corrected QTc’, which we defined as the percent change in mean QTc from baseline (pre-infusion) to post-infusion.

Doses and vehicles
For each dose of a given drug or vehicle, a separate group of animals (n = 5) was used; thus, each animal received only a single treatment of either drug or vehicle. All doses of all compounds or vehicles were infused intravenously at a rate of 0.1 mL min⁻¹ over a 10-min period (total volume = 1 mL). Drugs, doses and vehicles are summarized in Supplementary Table 1. The drug doses were selected to achieve reported human clinical plasma levels. Our past experience with this guinea-pig model indicated that a dose of 10 mg kg⁻¹ of a compound with molecular weight of about 400 resulted in plasma levels (Cmax) of 2–10 µM. In some instances, drug solubility in an appropriate intravenous formulation dictated the upper limit of the dose that could be administered. Physiological saline (0.9%) was used to dissolve water-soluble drugs. Three other vehicles were employed to achieve appropriate dosing for the drugs with poor solubility (see Table 4).

Analyses of drug concentrations in hERG solutions and in plasma of guinea-pigs
Drug concentrations were determined by atmospheric pressure ionization-liquid chromatography mass spectrometry (LCMS). Three samples of 1 mL for each concentration were taken from the reservoir and perfusate during the experiments for hERG. The samples were diluted with hERG buffer and analysed, or extracted with methyl tert-butyl ether (1 mL; Sigma-Aldrich, St Louis, MO, USA) before analysis. After extraction/dilution, the sample was injected onto the analytical column of an LCMS instrument (Hewlett-Packard Series 1100 Liquid Chromatograph Mass Selective Detector). Drugs and internal standards were detected as molecular ions ([M + H]⁺) in the positive selected ion-monitoring mode of the instrumentation. Drug concentration (nanogram or microgram per millilitre) in the samples was calculated with a calibration curve constructed from the peak area ratios (drug peak area/internal standard peak area) using a weighted linear regression. The concentration of drug in the sample was determined by interpolation from the regression line. The average differences between measured concentrations and expected concentrations were less than 8% (data not shown).

Internal standards of various compounds from this study (20 µL) were added to plasma samples (50–100 µL), vortexed and then precipitated with acetonitrile (Sigma-Aldrich; 1:3 v/v) or extracted with methyl tert-butyl ether (1 mL), centrifuged at 7280 g for 5 min, dried down in a TurboVap under nitrogen and reconstituted in mobile phase prior to analysis.

Statistical considerations
All statistical calculations were carried out using JMP 7.0 or SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA). For each compound, we performed ANOVA to compare baseline-corrected QTc for the low, medium and high doses to vehicle (compound-matched). Because we were interested in QTc increases, we performed one-sided comparisons to vehicle. We used P = 0.05 as our cutoff for determining statistically significant increases.

Results
Effects of the drugs on hERG
hERG currents were recorded under control conditions and during the application of the drugs at different concentrations. An example is shown in Figure 1, hERG tail currents were blocked by verapamil in a concentration-dependent manner with an IC₅₀ value of 0.94 µM. An IC₅₀ value was generated for each drug, except for class C drugs (amoxicillin, aspirin and captopril) where no hERG inhibition was observed. The percent inhibition of hERG current was taken
The IC50 for verapamil inhibition of hERG was 0.94 µM. The concentration-response curve was then fitted to a Hill equation as described in the Methods. In this example, the concentration at which the percent inhibition at each dose was calculated (n=4-8 cells for each concentration), and the concentration-response curve was then fitted to a Hill equation as described in the Methods. This pulse protocol was repeated every 10 sec while the cells were exposed to verapamil at different concentrations.

Figure 1: Effects of verapamil on hERG (human ether-a-go-go-related gene) potassium currents. (a) Stably transfected Chinese hamster ovary (CHO)-K1 cells were held at -80 mV, then stepped to +20 mV for 400 ms followed by a second pulse to -40 mV for 400 ms to elicit large, slowly deactivating hERG tail currents. This pulse protocol was repeated every 10 sec while the cells were exposed to verapamil at different concentrations. (b) The percent inhibition at each dose was calculated (n=4-8 cells for each concentration), and the concentration-response curve was then fitted to a Hill equation as described in the Methods. In this example, the IC50 for verapamil inhibition of hERG was 0.94 µM. The IC50 values for the other drugs evaluated in this study are listed in Table 2.

For these three drugs at the highest concentration permitted by their solubility. The effects on hERG currents of the drugs evaluated in this study are summarized in Table 2. The IC50 values for the drugs in all three groups are widely scattered. All drugs, except sotalol in group A, that induce QT prolongation and TdP incidence in humans had significant inhibitory effects on hERG. The IC50 values for group A drugs ranged from 15 nM to 556 µM. Most of the drugs in group A had potent hERG inhibitory effects. The drugs in group B that induced QT prolongation without TdP incidence showed significant hERG inhibitory effects as well. In general, the drugs in group C, which do not prolong QT and have no TdP reports, demonstrated significantly higher hERG IC50 values. The hERG IC50 values were not clearly separated among these three groups although there was a trend towards a decrease in hERG potency when moving from group A to group B.

### Table 2: Summary of hERG IC50 values and safety margins

| Drug          | hERG IC50 (µM) | Total safety margin (hERG IC50/total Cmax) | Free safety margin (hERG IC50/free Cmax) |
|---------------|----------------|------------------------------------------|----------------------------------------|
| Group A       |                |                                          |                                        |
| Amiodarone    | 0.546          | 0.15                                     | 3.7                                    |
| Cisapride     | 0.091          | 0.7                                      | 28                                     |
| Droperidol    | 0.307          | 0.075                                    | 0.749                                  |
| Halopenerid   | 0.015          | 0.1                                      | 1.4                                    |
| Quinidine     | 1.5            | 0.125                                    | 0.78                                   |
| D1-Sotalol    | 556            | 30.2                                     | 30.2                                   |
| Sparfloxacin  | 24             | 2.477                                    | 3.757                                  |
| Terfenadine   | 0.061          | 0.5                                      | 16.9                                   |
| Group B       |                |                                          |                                        |
| Moxifloxacin  | 235            | 27                                       | 42                                     |
| Tamoxifen     | 0.777          | 1.58                                     | 78.88                                  |
| Ziprasidone   | 0.165          | 0.573                                    | 286.45                                 |
| Group C       |                |                                          |                                        |
| Amoxicillin   | >50 000        | >315                                     | >384                                   |
| Aspirin       | >100 000       | >902                                     | >4512                                  |
| Captopril     | >3000          | >831                                     | >1382                                  |
| Propranolol   | 9.9            | 49.5                                     | 330                                    |
| Verapamil     | 0.94           | 1.6                                      | 14.2                                   |

Abbreviation: hERG, human ether-a-go-go-related gene.

**Calculation of safety margins between hERG IC50 and plasma Cmax**

In a survey of the literature, Redfern et al. reported that the margin between the hERG IC50 value and plasma exposure of the drug might be a valuable parameter for predicting the risk of QT prolongation and TdP induced by a hERG blocker. We calculated this margin, termed safety margin (SM), as the mean of IC50 value divided by the highest quoted value of the maximal plasma concentration in clinical use. In the case of terfenadine, the plasma concentration is from a case report of a drug interaction causing inhibition of cytochrome P450 enzymes; normally, the plasma levels of terfenadine are very low due to extensive first pass metabolism through this mechanism (Monahan et al., 1990). Two SMs were calculated for each drug using the total plasma concentration and unbound or free plasma concentration, which we refer to as the total SM (SM-total) and free SM (SM-free), respectively. As shown in Table 2, the total SMs for groups A and B were similar, which ranged from 0.07 to 30.2 for group A and from 0.6 to 27 for group B. Sotalol showed a markedly larger total margin of 30.2. The free SMs for group A were generally lower than group B (Figure 2). The free SMs for group A were in the range of 0.7 to 28. All of the free SMs for group B were greater than 30 with values ranging from 42 to 286. In group C, all free SMs were greater than 300, and the total SMs were larger than 50 with the exception of verapamil, which had smaller free (1.6) and total (14) SMs. The relationships between the free SMs for groups A, B and C are shown in Figure 2. Interestingly, groups B and C had significantly higher free SMs than group A. Each group differs from its neighbour by approximately one log unit (that is, 10-fold), which provides some heuristic support for considering cutoff values of 30
and 300 to distinguish between the free SMs of the three groups. These cutoff values are indicated by dashed lines in Figure 2. In fact, the difference of free SM between groups A and B was statistically significant ($P = 0.0005$) (data not shown).

**Effects of drugs on QTc interval in guinea-pigs**

Each of the drug doses was administered on a milligram per kilogram basis by slow intravenous infusion over 10 min. For each animal, baseline-corrected QTc was calculated as the percent change in mean QTc from baseline (that is, pre-infusion) to post-infusion (that is, from 10.5 to 40 min after the start of the 10-min infusion period). Examples for a drug from groups B and C are shown in Figure 3, and the baseline-corrected QTc results are listed in Table 3.

Group A drugs (agents associated with prolonged QT interval as well as TdP in humans), which included amiodarone, cisapride, droperidol, haloperidol, quinidine, sotalol, sparfloxacin and terfenadine caused significant ($P \leq 0.05$) increases in QTc above vehicle for at least one of the doses administered (Figure 4). Additionally, clear dose-response curves were noted for five of the eight group A drugs. The QTc changes with amiodarone were highly variable, as were those observed with the low dose of cisapride; this variability may have contributed to the lack of a clear dose–response relationship. Because of the marked bradycardia and resultant hypotension, the maximum dose of terfenadine was limited to 3 mg kg$^{-1}$, thus limiting the potential overall maximum changes. For the highest dose level of the eight drugs in group A, the mean baseline-corrected QTc values ranged from 6.9% (amiodarone) to 20.0% (sparfloxacin). The corresponding increases over vehicle ranged from 5.6% (amiodarone) to 19.6% (sparfloxacin) (Figure 4).

Group B drugs (agents associated with QTc prolongation, but not TdP in humans) included moxifloxacin, tamoxifen and ziprasidone. These agents elicited significant increases in QTc of a similar magnitude to the group A compounds. For all three group B drugs, QTc increased significantly above vehicle at both the second and third doses given. For the highest dose level of the three drugs in group B, the mean baseline-corrected QTc values ranged from 8.4% (tamoxifen) to 18.3% (moxifloxacin). The corresponding increases over vehicle ranged from 6.8% (tamoxifen) to 16.8% (moxifloxacin).

Group C drugs (agents not associated with QTc prolongation or TdP in clinical use) were captopril, verapamil, propranolol, amoxicillin and aspirin. For the highest dose level of these five drugs, the mean baseline-corrected QTc values ranged from −6.0% (captopril) to 3.9% (amoxicillin). The corresponding changes with vehicle ranged from −7.3% (captopril) to +2.4% (amoxicillin). No drugs in group C showed a significant increase in QTc over vehicle. In fact, QTc actually dropped below vehicle for captopril and verapamil. These decreases probably reflect significant haemodynamic changes and multiple ion channel (that is, calcium channel inhibition) effects, respectively.

In the past, when using this guinea-pig protocol with these or similar vehicles, we considered QTc increases of 5% over vehicle as pharmacologically important safety signals. Figure 4 shows baseline-corrected QTc, expressed as difference from vehicle, for every compound and dose. Doses with a significant ($P \leq 0.05$) increase over vehicle are marked with an asterisk. Every compound in groups A and B showed a statistically significant increase over vehicle for one or more doses, but none of the compounds in group C showed a statistically significant increase over vehicle. Additionally, every compound in groups A and B but none of the group C drugs exceeded the 5% risk signal for one or more doses.

No significant heart rate or blood pressure changes occurred in any of the vehicles used in these studies. The baseline blood pressures were stable and maintained within the ranges of 33–47 mm Hg for all groups, with mean values of 39 ± 3 mm Hg. Baselines heart rate ranges were 194–267 b.p.m. (beats per minute) with an overall group mean of 230 ± 16 b.p.m. QTc, heart rate and mean blood pressure changes for all drugs and vehicles are provided in Supplementary Tables 2–5.

**Discussion and conclusions**

Numerous reviews and studies have attempted to evaluate relationships between hERG potency, QTc changes in
mammals and QT prolongation/TdP incidence in humans (Carlsson, 2001; Hammond et al., 2001; Champeroux et al., 2005). However, comparisons of data from different sources and experimental protocols have been difficult. hERG IC$_{50}$ values for a drug can vary by up to 20-fold (Crumb, 2000; Kirsch et al., 2004). Often, as drug concentrations in the hERG perfusate are not analysed, their contribution to discrepancies in data from different sources is impossible to ascertain. The QTc data are even harder to compare across studies due to differences in species and experimental protocols. The present study is the first effort to correlate the outcomes of both in vitro functional hERG and in vivo QTc assays under defined conditions using specific protocols within the same laboratory for a variety of therapeutic agents with human data.

All drugs in groups A and B that caused QT prolongation in humans also showed concentration-dependent and pharmacologically relevant hERG inhibition. However, the IC$_{50}$ values were not clearly separated between groups A and B, suggesting that a risk of TdP cannot be predicted from hERG IC$_{50}$ values alone. The hERG liability may be placed in context with TdP incidence in humans by calculating an SM based on the IC$_{50}$ for inhibition of hERG divided by the maximal free plasma concentration of drug in clinical conditions (Webster et al., 2002; Redfern et al., 2003; De Bruin et al., 2005). In the present study, we demonstrated that an SM-free of 30 may differentiate between group A and B drugs (Figure 2), that is, drugs that induce TdP versus drugs that only cause QT prolongation. A 30-fold SM-free has also been derived by other groups based on literature surveys and analyses (Webster et al., 2002; Redfern et al., 2003).

Three group C drugs that do not cause QT prolongation in humans (aspirin, amoxicillin and captopril) also failed to potently inhibit hERG (IC$_{50}$ values above 1000 µM) and had SM-free above 300. These findings suggest that an SM-free of 300 or more may denote a compound devoid of a potential for causing QTc prolongation. Propranolol has not been reported to cause QT prolongation in clinical use. However, a recent report indicated that an overdose of propranolol in a patient led to QT prolongation (Farhangi and Sansone, 2003). We previously demonstrated that propranolol inhibits hERG potassium channels with an IC$_{50}$ of 10 µM, which is
Table 3  Summary of baseline-corrected QTc and peak plasma levels in the anaesthetized guinea-pig

| Dose (mg kg\(^{-1}\)) | Peak plasma level (\(\mu\text{g} (\text{mL})\)) | Baseline-corrected QTc (ms) |
|------------------------|-----------------------------------------------|-----------------------------|
| Group A                |                                               |                             |
| Amiodarone (vehicle 1) | 6.0 ± 1.4 (4)                                  | 8.0 ± 5.1 (5)               |
| 10                     | 58.3 ± 9.6 (3)                                 | 13.0 ± 5.2 (4)              |
| 20                     | 240 ± 52.7 (5)                                 | 6.9 ± 3.8 (5)               |
| Cisapride (vehicle 2)  | 0.037 ± 0.023 (4)                              | 8.5 ± 3.6 (5)               |
| 0.3                    | 0.129 ± 0.032 (4)                              | 6.6 ± 2.4 (5)               |
| 1                      | 0.496 ± 0.085 (5)                              | 18.2 ± 1.9 (5)              |
| Droperidol (vehicle 1) | 0.55 ± 0.07 (3)                                | 2.1 ± 3.2 (5)               |
| 0.1                    | 0.62 ± 0.05 (5)                                | 6.7 ± 2.3 (5)               |
| 0.3                    | 1.21 ± 0.34 (4)                                | 19.1 ± 4.8 (5)              |
| Haloperidol (vehicle 3)| 0.010 ± 0.003 (3)                              | 1.5 ± 0.8 (5)               |
| 0.1                    | 0.113 ± 0.012 (4)                              | 4.3 ± 1.2 (5)               |
| 1                      | 0.712 ± 0.137 (5)                              | 15.8 ± 3.6 (5)              |
| Quinidine (vehicle 2)  | 6.2 ± 0.08 (3)                                 | 8.5 ± 1.5 (5)               |
| 10                     | 27.8 ± 8.0 (5)                                 | 13.7 ± 2.9 (5)              |
| 30                     | Not determined                                 | 15.6 ± 4.9 (4)              |
| Sotalol (vehicle 1)    | 18.2 ± 1.5 (5)                                 | 18.1 ± 5.3 (5)              |
| 3                      | 41.3 ± 4.8 (4)                                 | 10.9 ± 1.8 (5)              |
| 10                     | 145.9 ± 16.6 (5)                               | 18.9 ± 6.6 (5)              |
| Sparfloxacin (vehicle 4)| 23.5 ± 4.2 (3)                                 | 6.6 ± 0.9 (5)               |
| 10                     | 80.4 ± 9.1 (5)                                 | 9.8 ± 1.7 (5)               |
| 30                     | 159.4 ± 22.4 (4)                               | 20.0 ± 3.3 (5)              |
| Terfenadine (vehicle 3)| 0.23 ± 0.03 (3)                                | 2.8 ± 0.8 (5)               |
| 1                      | 1.28 ± 0.07 (3)                                | 8.0 ± 2.0 (5)               |
| 3                      | 3.04 ± 1.07 (3)                                | 11.7 ± 1.2 (5)              |
| Group B                |                                               |                             |
| Mexifloxacin (vehicle 3)| 2.08 ± 0.28 (4)                                | 0.9 ± 1.7 (5)               |
| 5                      | 30.6 ± 7.2 (4)                                 | 11.2 ± 3.0 (5)              |
| 10                     | 80.5 ± 4.0 (5)                                 | 18.3 ± 4.4 (5)              |
| Tamoxifen (vehicle 3)  | 3.8 ± 0.8 (4)                                  | 2.2 ± 1.0 (5)               |
| 10                     | 10.5 ± 2.1 (5)                                 | 10.2 ± 3.9 (5)              |
| 30                     | 60.0 ± 20.0 (5)                                | 8.4 ± 1.4 (5)               |
| Ziprasidone (vehicle 1)| 1.1 ± 0.2 (4)                                  | 4.9 ± 2.0 (5)               |
| 0.3                    | 1.2 ± 0.1 (2)                                  | 7.0 ± 1.9 (5)               |
| 1                      | 4.0 ± 2.2 (2)                                  | 9.1 ± 1.0 (5)               |
| Group C                |                                               |                             |
| Amoxicillin (vehicle 3)| 4.8 ± 0.5 (5)                                  | 4.2 ± 2.0 (5)               |
| 10                     | 14.6 ± 1.4 (4)                                 | 4.4 ± 1.6 (5)               |
| 20                     | 30.3 ± 2.5 (5)                                 | 3.9 ± 0.3 (5)               |
| Aspirin (vehicle 1)    | 31.1 ± 2.3 (5)                                 | 0.5 ± 0.8 (5)               |
| 3                      | 74.6 ± 2.1 (5)                                 | 1.3 ± 0.6 (5)               |
| 10                     | 468 ± 78 (4)                                   | 2.5 ± 1.8 (5)               |

Table 3  Continued

| Dose (mg kg\(^{-1}\)) | Peak plasma level (\(\mu\text{g} (\text{mL})\)) | Baseline-corrected QTc (ms) |
|------------------------|-----------------------------------------------|-----------------------------|
| Captopril (vehicle 1)  | 57.8 ± 1.6 (2)                                 | 0.0 ± 0.9 (5)               |
| 10                     | 142 ± 15 (2)                                   | −1.3 ± 1.4 (5)              |
| 30                     | 313 ± 112 (2)                                  | −6.0 ± 1.9 (4)              |
| Propranolol (vehicle 1)| 0.50 ± 0.03 (3)                                | −1.6 ± 1.2 (5)              |
| 1                      | 1.84 ± 0.41 (3)                                | 2.7 ± 1.3 (5)               |
| 3                      | 4.65 ± 0.40 (5)                                | 1.1 ± 1.4 (5)               |
| Verapamil (vehicle 1)  | 0.48 ± 0.04 (4)                                | −0.9 ± 0.7 (5)              |
| 0.5                    | 0.73 ± 0.03 (2)                                | −2.3 ± 1.7 (5)              |
| 1                      | 1.97 ± 0.37 (4)                                | −0.4 ± 2.0 (5)              |

Abbreviation: QTc, heart rate correct QT interval of the ECG.

Table 4 Effects of vehicles on baseline-corrected QTc in the anaesthetized guinea pig

| Vehicles Composition | Baseline-corrected QTc (ms) |
|----------------------|-----------------------------|
| 0.9% NaCl            | 1.3 ± 0.8 (5)               |
| 15% HP-beta-cyclodextrin in 25 mm methanesulphonic acid | 1.5 ± 0.1 (5) |
| 5% DMSO-10% SBE-cyclodextrin in 5 mm methanesulphonic acid | 1.6 ± 0.8 (5) |
| 10 mg mL\(^{-1}\) lactic acid in 5% dextrose in water | 0.4 ± 1.2 (5) |

Abbreviation: QTc, heart rate correct QT interval of the ECG.

about 300- to S30-fold higher than its maximum free plasma concentration at therapeutic doses. Therefore, propranolol is unlikely to induce QTc prolongation at therapeutic doses (Yao et al., 2005). In general, the SM-free value of a drug candidate should exceed 300 to be considered safe from causing QT prolongation. In our experience, for typical drug projects in metabolic diseases, a compound that satisfies SM-free > 300 usually must have a hERG IC\(_{50}\) greater than 10\(\mu\)M. The free plasma C\(_{\text{max}}\) of the drug at therapeutic exposures can be obtained from appropriate animal models of efficacy utilized during the early stages of drug development.

The guinea-pig is an established small animal model for cardiac research because its cardiac ion channel profile (with the exception of I\(_{\text{TCF}}\)) resembles that of humans (Busch et al., 1994), as does its ECG, with easily identifiable P, QRS and T waves. During the lead-optimization phase of drug discovery, drug availability is usually limited and a small, inexpensive animal model such as the guinea-pig that can provide QTc prolongation data alongside pharmacokinetic measures is highly desirable. Both conscious and anaesthetized guinea-pigs have been used to examine the effects of pro-arrhythmic drugs on the QT interval or the monophasic action potential duration in vivo (Lu et al., 1993; Sosunov et al., 1996; Minematsu et al., 1999). The draft guideline ICH S7B Step 2 Revision (2004) allows an anaesthetized model to be used for QT measurements, and the Japanese Guidelines for Non-clinical Studies of Drugs Manual (1995) advises the use of anaesthetized animals. Data from the Japan Manufacturers’
Association PRODACT Initiative confirmed that the anaesthetized dog is a sensitive model for detecting drug-induced effects on QT interval (Tashibu et al., 2005). QTc prolongation has been shown in guinea-pigs for terfenadine, cisapride and sotalol, as it has in humans (Gras and Llenas, 1999; Kii et al., 2001; Hamlin et al., 2003; Fossa et al., 2004; Testai et al., 2004; Hauser et al., 2005). Isolated guinea-pig heart preparations have been used for studying pro-arrhythmic effects and TdP potential of compounds (Gerhardt et al., 1998).

Certain elements of the specific protocols used in our hERG and guinea-pig studies are critical to the sensitivity, precision and accuracy of the readouts, which in turn, directly impact the correlation analyses. We employed a 400-ms pulse protocol in our hERG protocol because the duration is similar to the cardiac action potential. Longer duration pulse protocols are commonly used to test drug effects during supramaximal channel activation. Although our shorter pulse duration protocol could potentially underestimate the IC50 values for some compounds, the strategy that we have outlined here is based on correlation analyses using these IC50 values; one could use longer pulse protocols, provided correlation analyses are done and appropriate adjustments are made to the evaluation strategy outlined in Figure 5.

Specific elements of the guinea-pig protocol contributing to the precision of the data include anaesthesia, ventilation and a single-dose testing regimen. Inactin provides a rapid induction, whereas urethane provides a uniform maintenance of anaesthesia with minimal inhibition of the autonomic system. Both anaesthetics lack any reported effects on QTc, unlike other anaesthetic agents, such as pentobarbitone, isoflurane and halothane. Artificial ventilation ensures that cardiovascular effects secondary to respiratory depression are minimized. We avoided multiple dosing to the same animal (Hauser et al., 2005) and instead used a single dose per animal to enable accurate assessments of plasma concentrations of drug. We also limited the volume infused (1 mL) to minimize effects on haemodynamic function and reduce the experimental duration of the preparation to minimize its deterioration over time.

Figure 4 Summary of QTc (heart rate corrected QT interval of the ECG) expressed as differences from vehicle. The y axis shows the mean difference from vehicle (of baseline-corrected QTc) for each drug and the low (L), medium (M) and high (H) doses (Table 3) that were tested in the anaesthetized guinea-pig model. QTc values that are significantly higher than vehicle (P<0.05) are indicated by asterisks. Every drug in groups A and B showed at least one significant increase over vehicle, but none of the drugs in group C had any significant increases over vehicle.

Figure 5 A testing strategy incorporating the hERG (human ether-a-go-go-related gene) electrophysiology and anaesthetized guinea-pig QTc (heart rate corrected QT interval of the ECG) assays. The solid lines represent the standard progression path, whereas the dashed lines represent exceptions on a case-by-case basis. Compounds are initially evaluated in a hERG electrophysiology assay conducted using the defined protocol described in Methods. Compounds with hERG IC50 values of >10µM are usually withheld. Compounds with IC50 values between 1 and 10µM are evaluated for their potential to prolong the QTc in a specific anaesthetized guinea-pig model (see Methods for protocol details). If a compound is found to prolong QTc in this model, an in vivo safety margin (SM) is calculated by dividing the peak drug concentration obtained from an anaesthetized guinea-pig study (where the QTc increased by more than 5%) by the peak drug concentration obtained during an efficacy study in an appropriate animal model. If the SM is greater than 30, the compound is further progressed; if the SM is less than 30, the compound is put on ‘hold’, and research continues for an alternative clinical candidate.
Despite its many advantages, one limitation of this guinea-pig model is the requirement that the test compound be soluble in a vehicle suitable for slow intravenous infusion. The present study showed that our anaesthetized guinea-pig model mimics drug-induced QTc prolongation in humans. An important finding of our study was that a 5% increase in QTc (over vehicle) is of sufficient magnitude to detect significant QTc prolongation in this model. Group C drugs, including amoxicillin, aspirin, captopril, propranolol and verapamil, which are not associated with QT prolongation in humans, did not reach the 5% increase of QTc in the guinea-pig model, whereas every compound in groups A and B exceeded the 5% risk signal for one or more doses. These observations would indicate that the cutoff value of 5% is a reasonable threshold for detecting compounds with potential clinical QT risk. Furthermore, our guinea-pig model elicited dose-dependent QTc prolongation with moxifloxacin, a commonly utilized positive control in ‘Thorough QT Studies’ for detecting QT effects of investigational drugs in clinical trials. A single 400 mg dose of moxifloxacin, which prolongs the QT interval in humans with a plasma Cmax of approximately 7 μM, was mimicked by our guinea-pig model (Figure 3a and Table 3). A poor understanding of the mechanisms underlying TdP has always imposed limitations for predicting its risk through evaluation of QT interval. Our experience suggests that excessive QT prolongation in conjunction with drug exposure is likely to be associated with TdP. Pro-arrhythmic paradigms, such as isolated canine Purkinje fibres (Champeroux et al., 2005), and rabbit heart (Hondeghem and Hoffmann, 2003; Liu et al., 2006) or other electrocardiographic measures such as transmural dispersion have been claimed to be better surrogate markers for TdP; the latter has not been extensively validated in the clinic (Antzelevitch, 2001). Hondeghem and colleagues proposed triangulation, reverse use dependency, electrical instability of the action potential, and dispersion as a potential specific TdP predictor (Shah and Hondeghem, 2005). A major limitation of all in vitro preparations is the absence of any plasma drug exposure data for estimating in vivo safety ratios. To date, measurement of the QT interval in the clinic remains the only acceptable indicator of TdP liability. Moreover, the requirement of the Thorough QT Study in humans for many drugs is a reflection of the inefficiency of preclinical guidelines to predict QT prolongation in humans, even though studies of 19 compounds showed a satisfactory correlation between TQT and preclinical results (Cavero, 2008). Using these analyses of hERG inhibitory potency in conjunction with drug exposures and QTc interval changes in the anaesthetized guinea-pig model, we have developed a strategy, schematically depicted in Figure 5, for selecting drug candidates during early drug development with a reduced risk of human QT prolongation. In our experience, compounds with hERG IC50 values of less than 1 μM usually prolong QTc in the anaesthetized guinea-pig. Such compounds are usually not progressed unless they are potent at the primary target and efficacious in an animal model at low plasma exposures. Compounds with hERG IC50 values above 10 μM usually do not prolong QTc in anaesthetized guinea-pigs. However, certain classes of compounds, such as antibiotics, can achieve high plasma levels and prolong QTc, although they might be weak hERG inhibitors. Compounds with hERG IC50 values between 1 and 10 μM are evaluated in anaesthetized guinea-pigs. If a compound is found to prolong QTc in this model, then an in vivo SM (SMiv) is calculated for decision-making, as elaborated in Figure 5. Although hERG inhibition may be useful for predicting QTc prolongation, it cannot be considered in isolation. Verapamil is not associated with QT prolongation and TdP in humans, but inhibits hERG with an IC50 of 0.94 μM (Figure 1 and Table 2). However, as verapamil blocks cardiac calcium channels—its primary mechanism, leading to QT shortening—as well as hERG, the net effect on cardiac action potential duration is not markedly changed. In agreement with clinical observations, verapamil did not prolong the QT interval in our guinea-pig model. These findings underscore the importance of considering other cardiac ion channels for evaluation of drug safety (Fermini and Fossa, 2003; Bass et al., 2005; Salama and London, 2007). At the GlaxoSmithKline Center for Excellence in Drug Discovery (Research Triangle Park, NC, USA) we have used this strategy to successfully evaluate and select a variety of drug candidates for human clinical trials over the past 10 years. Subsequent data have repeatedly confirmed our predictions of risk for QTc prolongation of these drugs in humans.

Acknowledgements

We thank Dr Paul Feldman for his review of the paper and helpful comments and suggestions.

Conflict of interest

The authors state no conflict of interest.

References

Antzelevitch C (2001). Tpeak–Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 31: 555–557.

Aweka E, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD et al. (2000). The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 49: 275–33S.

Bass AS, Tomasselli G, Bullingham III R, Knister LB (2005). Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 52: 12–21.

Busch AE, Malloy K, Grob VJ, Varnum MD, Adelman JP, Maylie J (1994). The novel class III antiarrhythmics NE-10064 and NE10133 inhibit ISk channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. Biochem Biophys Res Commun 202: 265–270.

Carlsson L (2001). Drug-induced torsade de pointes: the perspectives of industry. Eur Heart J (Supplement K) 3: K114–K120.

Cavero I (2008). Safety Pharmacology Society: 7th annual meeting 19–20 September. Expert Opin Drug Safety 7: 91–100.

Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY et al. (2005). Prediction of the risk of torsade de pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol 144: 376–385.

Committee for Proprietary Medicinal Products (1997). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP
document number: CPMP/986/96. European Agency for the Evaluation of Medicinal Products: London.
Crumb W, Caverio I (1999). QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today 2: 270–280.
Crumb WJ (2000). Loratadine blockade of K+ channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292: 261–264.
Darpo B (2001). Spectrum of drugs prolonging QT interval and the incidence of torsades de points. Eur Heart J [Supplement K] 3: K70–K80.
De la Ros Blin ML, Pettersson LM, Meyboom RHB, Hoes AW, Leufkens HGM (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590–597.
Editorial Supervision by Pharmaceutical and Cosmetics Division, Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1995). Japanese Guidelines for Nonclinical Studies of Drugs Manual: Yakugaku Nippo Ltd., Tokyo.
Farhangi V, Sansone RA (2003). QTc prolongation due to propranololdose. Int J Psychiatry Med 33: 201–202.
Ferrarini M, Fossa AA (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2: 439–447.
Fischer M, Bonnet F, Trang H, Jacob L, Levron JC, Flaisber B et al. (1986). The pharmacokinetics of droperidol in anesthetized patients. Anesthesiology 64: 486–489.
Fossa AA, Wisalowski T, Wolfgang E, Wang E, Avery M, Raunig DL et al. (2004). Differential effect of HERG blocking agents on cardiac electrical alternant in the guinea pig. Eur J Pharmacol 486: 209–221.
Gerhardy A, Scholtysik G, Schaad A, Haltiner R, Hess T (1998). Generating and influencing torsades de points—like polymorphic ventricular tachycardia in isolated guinea pig hearts. Basic Res Cardiol 93: 285–294.
González MA, Estes K (1998). Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther 36: 292–300.
Gras J, Llanes J (1999). Effects of H1 antihistamines on animal models of QTc prolongation. Drug Safety 21: 39–44.
Hamlin RL, Kijtawornrat A, Keene BW, Hamlin DM (2003). QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol Sci 76: 437–442.
Hammond TG, Carlson L, Davis AS, Lynch WG, MacKenzie I, Redfern WS et al. (2001). Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 49: 741–750.
Hardman JG, Limbird LE (2006a). Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York, pp 955.
Hardman JG, Limbird LE (2006b). Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York, pp 955.
Hauser DS, Stade M, Schmidt A, Hanauer G (2005). Cardiovascular parameters in anesthetized guinea pigs: a safety pharmacology screening model. J Pharmacol Toxicol Methods 52: 106–114.
Hondegem LM, Hofmann P (2003). Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependency and instability. J Cardiovasc Pharmacol 41: 14–24.
Kii Y, Nakatsui K, Nose I, Yabuuchi M, Mizuki Y, Tto T (2001). Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anesthetized rats and guinea-pigs and conscious cats. Pharmacol Toxicol 89: 96–103.
Kirsch GL, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochlan MC et al. (2004). Variability in the measurement of HERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50: 93–101.
Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3: 948–956.
Lu H, Remesnyek P, De Clerck D (1993). Inhibition of Na+/Ca2+ overload with R56865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. Eur J Pharmacol 253: 89–93.
Meulemans W, Van Peer A, Hendrickx J, Lauwers W, Swensen E, Bockx M et al. (1988). Excetion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 16: 403–409.
Miceli JJ, Smith M, Robarge L, Morse T, Laurent A (2000). The effects of ketonozonale on zipsidone pharmacokinetics—a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 49: 715–765.
Minematsu T, Ohtani H, Sato H, Iga T (1999). Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci 65: PL197–PL202.
Monahan BP, Ferguson CL, Killeavey ES, Lloyd BK, Troy J, Cantilena LR (1990). Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788–2790.
Morganroth J, Talbot GH, Dorr MB, Johnson RD, Geary W, Magner D (1999). Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin Ther 21: 818–828.
Redfern WS, Carlsson L, Davis AS, Lynch WG, Mackenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32–45.
Salama G, London B (2007). Mouse models of long QT syndrome. J Physiol 578: 43–53.
Shah RR, Hondeghem LM (2005). Refining detection of drug-induced proarrhythmia: QT interval and TriAD. Heart Rhythm 2: 758–772.
Shimada J, Nogita T, Ishibashi Y (1993). Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 25: 358–369.
Song JC, White CM (2002). Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors. Clin Pharmacol 41: 207–224.
Sosunov EA, Anyukhovsky P, Rosen MR (1996). Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. J Pharmacol Exp Ther 278: 906–912.
Tashibu H, Miyazaki H, Aoki K, Akie Y, Yamamoto K (2005). QT PRODCT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 99: 473–486.
Testai L, Calderone V, Salovieri A, Breschi MC, Nieri P, Martinotti E (2004). QT prolongation in anesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J Appl Toxicol 24: 217–222.
Webster K, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsade de points. Curr Opin Drug Discov Dev 5: 116–126.
Yao X, McIntyre MS, Lang DG, Song IH, Becherer JD, Hashim MA (2005). Propranolol inhibits the human ether-a-go-go-related gene potassium channels. Eur J Pharmacol 519: 208–211.

Supplementary Information accompanies the paper on British Journal of Pharmacology website (http://www.nature.com/bjp)

This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Licence. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

BPOpen

This article is available free of charge on the BJP website (http://www.bjpharmacol.org).